80
Participants
Start Date
June 22, 2022
Primary Completion Date
November 30, 2025
Study Completion Date
January 31, 2026
Semaglutide Injectable Product
Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
Standard of care
Diet and exercise advice for 40 weeks
RECRUITING
Mater Misericordiae University Hospital, Dublin
University of Copenhagen
OTHER
Rush University Medical Center
OTHER
University College Dublin
OTHER